SCHEMBL384755

SCHEMBL384755

ClCCSCCSCCCl

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11173104 1.00 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
SCHEMBL19742962 1.00 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
SCHEMBL9117801 0.95 ALDH1A1 (0.36) ALDH1A1TSHRTDP1
SCHEMBL43809 0.95
Water SCHEMBL23801211 0.91 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
SCHEMBL4952021 0.89 ALDH1A1 (0.31) ALDH1A1TSHRTDP1
SCHEMBL389363 0.84 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
SCHEMBL377335 0.84 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
Ethyl Chloride SCHEMBL4775177 0.84 TSHR (0.33) ALDH1A1TSHRTDP1
SCHEMBL11300184 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12343351-B2 Pulmonary function treatment RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-01 US claimed
EP-3914286-B1 METHODS OF MITIGATING TOXIC EFFECTS OF VESICANTS AND CAUSTIC GAS JANSSEN PHARMACEUTICA NV (BE) 2025-05-07 EP claimed
US-20230302018-A1 PULMONARY FUNCTION TREATMENT RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-09-28 US claimed
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds SYNEDGEN, INC. (US) 2023-08-08 US claimed
US-11273203-B2 Methods of mitigating toxic effects of vesicants and caustic gas JANSSEN PHARMACEUTICA NV (BE) 2022-03-15 US claimed
US-11071795-B2 Indicating devices based on etching of metals JP LABORATORIES INC. (US) 2021-07-27 US claimed
US-20180024011-A1 Indicating Devices Based on Etching of Metals JP LABORATORIES INC. 2018-01-25 US claimed
US-8557730-B2 Composition and process for making the composition MOLYCORP MINERALS, LLC (US) 2013-10-15 US claimed
US-8343437-B2 Monitoring system based on etching of metals JP LABORATORIES, INC. (US) 2013-01-01 US claimed
US-8252087-B2 Process and apparatus for treating a gas containing a contaminant MOLYCORP MINERALS, LLC (US) 2012-08-28 US claimed
US-20100284905-A1 Methods and Agents for Inhibiting Tumor Growth by Targeting the SSDNA Replication Intermediate of Tumor Stem Cells Massachusetts Institute of Tehnology 2010-11-11 US claimed
US-20100168498-A1 APPARATUS AND PROCESS FOR TREATING AN AQUEOUS SOLUTION CONTAINING CHEMICAL CONTAMINANTS MOLYCORP MINERALS, LLC (US) 2010-07-01 US claimed
EP-2171448-A2 METHODS AND AGENTS FOR INHIBITING TUMOR GROWTH BY TARGETING THE SSDNA REPLICATION INTERMEDIATE OF TUMOR STEM CELLS Massachusetts Institute of Technology (US) 2010-04-07 EP claimed
US-20090301382-A1 Monitoring System Based on Etching of Metals JP LABORATORIES, INC 2009-12-10 US claimed
WO-2008156629-A2 METHODS AND AGENTS FOR INHIBITING TUMOR GROWTH BY TARGETING THE SSDNA REPLICATION INTERMEDIATE OF TUMOR STEM CELLS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-12-24 WO claimed
US-20070114121-A1 Signal activated decontaminating coating CROSSLINK POLYMER RESEARCH (US) 2007-05-24 US claimed
EP-1166825-A1 Formulations for neutralization of chemical and biological toxants Sandia Corporation (US) 2002-01-02 EP claimed
EP-0783682-B1 DETECTION OF SULPHUR CONTAINING COMPOUNDS SECR DEFENCE (GB) 1999-07-21 EP claimed
EP-4743121-A1 METAL SCAVENGER PharmaLundensis AB (SE) 2026-05-20 EP disclosed
US-4083692-A Detection and estimation of microquantities of alkylating agents THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1978-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11273203-B2 Methods of mitigating toxic effects of vesicants and caustic gas CXCL8, GPR88, TPSG1 ALDH1A1 802/4885TSHR 1286/4885TDP1 1658/4885
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds CHIA, MMP8, CHIT1 ALDH1A1 2248/4885TSHR 4714/4885TDP1 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.